Somatostatin inhibits the dermorphin-stimulated thyrotropin release in man.
We have studied the effect of the intravenous administration of somatostatin (SRIF) on the thyrotropin (TSH) response to intravenous dermorphin (D), a new potent opioid peptide, in 7 healthy men. D significantly increased the serum TSH concentration. SRIF administration prior to, during and after D completely prevented the D-induced rise in serum TSH. These results confirm that D stimulates TSH release in man and that this stimulatory effect can be prevented by SRIF.
degli Uberti
E C
EC
Roti
E
E
Trasforini
G
G
Salvadori
S
S
Margutti
A
A
Robuschi
G
G
Tomatis
R
R
Gnudi
A
A
Pansini
R
R
Braverman
L E
LE
D000293:Adolescent; D000328:Adult; D004723:Endorphins / Q000502:physiology; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D018847:Opioid Peptides; D013004:Somatostatin / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood*
D004723:Endorphins; D009842:Oligopeptides; D018847:Opioid Peptides; C030058:dermorphin; D013004:Somatostatin; D013972:Thyrotropin